Differential Expression of Interleukin-2 and Gamma Interferon in Human Immunodeficiency Virus Disease

JOURNAL OF VIROLOGY, Oct. 2001, p. 9983–9985 0022-538X/01/$04.00⫹0 DOI: 10.1128/JVI.75.20.9983–9985.2001 Copyright © 2001, American Society for Microbiology. All Rights Reserved.

Vol. 75, No. 20

Differential Expression of Interleukin-2 and Gamma Interferon in Human Immunodeficiency Virus Disease SCOTT F. SIEG,1 DOUGLAS A. BAZDAR,1 CLIFFORD V. HARDING,2

AND

MICHAEL M. LEDERMAN1*

1

Department of Medicine, Division of Infectious Diseases, and Department of Pathology,2 Center for AIDS Research, Case Western Reserve University, Cleveland, Ohio 44106 Received 7 March 2001/Accepted 28 June 2001

CD4⫹ T-cell function in human immunodeficiency virus (HIV) disease is markedly impaired. CD4⫹ T cells from HIVinfected individuals fail to proliferate appropriately following stimulation with antigen or mitogen (2, 6, 7, 9, 10, 12) and display enhanced susceptibility to apoptosis (5, 8). These defects are accompanied by reduced production of the immunoregulatory cytokine interleukin-2 (IL-2) (2, 7). IL-2 production may be critical in HIV disease, since this cytokine acts as an important T-cell growth factor. Moreover, the addition of exogenous IL-2 to patient T cells enhances T-cell proliferation (12) and protects from apoptosis (1) in vitro. Thus, production of IL-2 by patient T cells may be especially important for proper immune function. Recent progress in intracellular cytokine staining has allowed for the evaluation of cytokine production by defined T-cell populations on a single-cell basis. This technique has been used to evaluate immune responsiveness in HIV-infected patients (3, 4, 11). Commonly, gamma interferon (IFN-␥) production by patient T cells is used to measure immune responses to recall antigen, HIV antigen, or mitogens in vitro. The relative ease of detecting IFN-␥ makes it a useful and sensitive tool for identifying antigen-reactive cells. Despite the practical advantages of detecting IFN-␥ production in T-cell populations, measuring production of this cytokine may not provide a complete determination of functionality of cells from HIV-infected patients. T cells from HIV-infected patients with advanced disease have poor proliferation responses to HIV antigens and yet may respond by producing IFN-␥ (11). We have described poor proliferation in CD4⫹ T cells from HIV-infected patients even though these cells express CD25 and CD69 activation markers following T-cell receptor stimulation (13). Thus, some functional re-

sponses, such as IFN-␥ production or expression of CD25 and CD69, may be maintained in HIV disease whereas others, such as proliferation, are lost. Contrary to this suggestion, it has been argued that proliferation failure may be an artifact of prolonged cell culture, during which cells may be predisposed to an early apoptotic death (11). The detection of intracellular cytokine avoids these complications, since the assay can be performed in 5 to 6 h ex vivo. Therefore, it could be argued that cytokine responses better reflect the true nature of immune recognition and function in HIV disease. To determine whether selective defects in cytokine production might be present in HIV disease, we tested the capacity of patient CD4⫹ T cells to produce IL-2 and IFN-␥ in response to staphylococcal enterotoxin B (SEB), a superantigen with potent cytokine-inducing potential. Whole blood from HIV-infected patients or healthy controls was stimulated with SEB and subsequently treated with brefeldin A to prevent the release of cytokine from intracellular stores. IFN-␥ and IL-2 production was measured in CD4⫹ CD69⫹ cells by three-color flow cytometry. CD69 is a marker of T-cell activation and is commonly used to enrich for antigen-reactive cells in intracellular cytokine assays. In comparison to healthy donor cells, patient CD69⫹ cells tended to have reduced IL-2 responses, but relatively normal IFN-␥ responses, on a per cell basis (Fig. 1 and Table 1). The addition of anti-CD28 antibody at 1 ␮g/ml to the stimulation had little effect on cytokine production in response to SEB (data not shown). Thus, with CD69 as a denominator of activated cells, it was clear that most patient responses were suboptimal in IL-2 production but normal in IFN-␥ production. The differential production of IFN-␥ and IL-2 in HIV disease was even more dramatically illustrated by using IFN-␥producing cells as the denominator for the enumeration of IL-2-producing cells. In HIV-infected patients, the proportion of IFN-␥-producing cells that could simultaneously make IL-2 was markedly reduced compared to cells from healthy donors (Fig. 2 and Table 1). Again, addition of anti-CD28 antibody

* Corresponding author. Mailing address: Division of Infectious Diseases, University Hospitals of Cleveland, AIDS Clinical Trials Unit, Foley Building, 2061 Cornell Rd., Cleveland, OH 44106. Phone: (216) 844-8175. Fax: (216) 844-5523. E-mail: lederman.michael @clevelandactu.org. 9983

Downloaded from http://jvi.asm.org/ on July 2, 2015 by guest

Subnormal T-cell production of interleukin-2 (IL-2) in human immunodeficiency virus (HIV) disease has been described; however, it is not clear whether failure to synthesize IL-2 represents a selective or global defect in T-cell cytokine production. We evaluated the intracellular production of gamma interferon (IFN-␥) and IL-2 in CD4ⴙ cells that were stimulated with staphylococcal enterotoxin B or cytomegalovirus antigen. Strikingly, IFN-␥ and IL-2 are differentially regulated in T cells of HIV-infected patients such that the numbers of CD69ⴙ cells or IFN-␥-positive cells that make IL-2 are proportionally decreased in CD4ⴙ T cells from HIV-infected patients. These findings demonstrate a selective defect in IL-2 production and suggest that enumeration of IFN-␥-producing cells in response to T-cell receptor stimulation, while providing some estimate of antigenreactive cell frequency, may not reflect or predict “normal” T-cell function in HIV-infected patients.

9984

NOTES

J. VIROL. TABLE 1. Expression of IL-2 and IFN-␥ following SEB stimulationa Patient or control

Patients 536 248 138 121 261 113 091 107

Mean Median

made little difference (data not shown). These observations suggest that CD4⫹ T cells activated through T-cell receptor stimulation to produce IFN-␥ have a decreased capacity to make IL-2 in HIV disease. Cytokine production following superantigen stimulation may differ from that induced by antigen stimulation, since superantigen does not require processing by professional antigen-presenting cells and can elicit responses from either naı¨ve or memory cell populations with the appropriate T-cell receptor variable chain. Therefore, to determine whether differential production of IL-2 and IFN-␥ might also be observed in response to antigen, whole blood was exposed to cytomegalovirus (CMV) antigen and assessed for cytokine production. Following CMV antigen stimulation, patient cells demonstrated a proportional reduction in IL-2 production both in the CD69⫹ T-cell population and in IFN-␥ producing cells; however, the IFN-␥ responses of CD69⫹ cells in patients and in controls were similar (Fig. 3 and Table 2). These results are consistent with what was found with SEB stimulation and indicate that the differential expression of IFN-␥ and IL-2 is also seen in memory CD4⫹ T cells responding to antigen in HIVinfected patients. While diminished IL-2 expression has been noted in HIV disease (2, 7), this study clearly demonstrates a selective impairment in IL-2 expression by CD4⫹ T cells in HIV disease on an individual-cell basis following T-cell receptor activation. Importantly, these analyses were performed under conditions in which cells were incubated for a short time and maintained in whole blood. Therefore, differences in production of IL-2

Controls 1 2 3 4 5 6 7 8 Mean Median

⬍400 15,000 21,000 25,000 32,000 65,000 97,000 520,000 28,500

CD69⫹ % IL-2⫹

CD69⫹ % IFN-␥⫹

486 202 309 460 680 250 190 112

15.1 11.5 11.8 6.4 9.0 21.7 9 11.7

25.5 32.1 26.5 36.1 ND 52.6 22 12.3

ND 12.3 12.4 5.9 21 5.7

275.9

12.0ⴱ 11.6

29.6 26.5

13.6† 12.35

16.7 11.2 19.4 9.7 22 18.3 25 21

17.1 24.8 25.4 48 29 25.5 ND ND

34.4 32 43.2 39 ND 29 ND 20.0

17.9 18.3

28.3 25.5

33.0 33.2

No. of CD4 cells/␮l

IFN-␥⫹ % IL-2⫹

24

a P values from two-tailed t tests of comparisons between the average responses of patients and healthy donors are as follows: ⴱ, P ⬍ 0.03; †, P ⬍ 0.001. ND, not done.

and IFN-␥ cannot be explained by culture-induced artifacts, as might occur in proliferation assays of long duration. Important inferences can be drawn from the results of this study, which shows that CD4⫹ T cells from HIV-infected patients maintain a selective defect in IL-2 production while

FIG. 2. Reduced proportions of IFN-␥-producing cells make IL-2 in CD4⫹ T cells from HIV-infected patients. Whole blood was stimulated and processed as described in the legend to Fig. 1 except that cells were stained with anti-CD4 peridinin chlorophyll protein-conjugated antibody, anti-IFN-␥ phycoerythrin-conjugated antibody, and anti-IL-2 fluorescein isothiocyanate-conjugated antibody. The numbers shown indicate the percentages of IFN-␥-producing cells that were IL-2 positive following SEB stimulation.

Downloaded from http://jvi.asm.org/ on July 2, 2015 by guest

FIG. 1. Differential production of IL-2 and IFN-␥ in CD69⫹ cells. Whole blood was incubated with SEB (Sigma) (5 ␮g/ml) for 2 h before Golgi-stop reagent (BD Pharmingen) containing brefeldin A was added. Cells were incubated for an additional 3 h, at which time the cells were treated with Facs lyse solution (Becton Dickinson) and frozen at ⫺86°C overnight. Frozen cells were thawed and treated with Facs permeabilizing solution (Becton Dickinson) and then stained with antiCD69 phycoerythrin-conjugated antibody, anti-CD4 peridinin chlorophyll protein-conjugated antibody, and either anti-IL-2 or anti-IFN-␥ fluorescein isothiocyanate-conjugated antibody (Becton Dickinson). Cells stained with isotype control antibodies were used to establish quadrants. Unstimulated cells in this case were exposed to anti-CD28 antibody (1 ␮g/ml) to control for additional experiments in which cells were stimulated with SEB plus anti-CD28 antibody (data not shown). The numbers shown indicate the percentages of CD69⫹ cells that were IL-2 positive following SEB stimulation.

HIV RNA in plasma (no. of copies/ml)

VOL. 75, 2001

NOTES

9985

vaccine responses that have been observed in HIV-infected patients (14). Furthermore, while T-cell production of IFN-␥ may provide an indication that T cells with defined receptor specificity are present, enumeration of these cells may not provide an appropriate demonstration of functional immune competence in HIV disease. We thank Robert Asaad for assistance in acquiring blood samples. Scott Sieg is supported by National Research Service grant AI0702421, from the National Institutes of Health. These studies were also supported by the Case Western Reserve University Center for AIDS Research (grant AI36219). REFERENCES

IFN-␥ expression is preserved. As IL-2 is a critical mediator of immune competence in health and disease, this selective defect in IL-2 expression after T-cell receptor stimulation may be a key determinant of immune dysfunction in HIV infection. Selective impairment of IL-2 production in memory cells also might limit appropriate expansion of antigen-reactive cells following in vivo challenge. This may in part explain the reduced TABLE 2. Expression of IL-2 and IFN-␥ following CMV stimulation HIV RNA in plasma (no. of copies/ml)

No. of CD4 cells/␮l

CD69⫹ % IL-2⫹

CD69⫹ % IFN-␥⫹

IFN-␥⫹ % IL-2⫹

141 150 266 265 164 195

23,000 135,000 91,000 196,000 93,000 70,000

598 344 784 63 104 464

20.5 10 5 13.5 11.0 ND

90.2 85 70 53 45 ND

24 9 8 22 NDa 33.6

Mean

101,000

393

12.0

68.6

19.3

Controls 1 2 3 4

57 24 19.4 ND

62 53 50 ND

41 26 ND 62

Mean

33.5

55

43

Patient or control

Patients

a

ND, not done.

Downloaded from http://jvi.asm.org/ on July 2, 2015 by guest

FIG. 3. Reduced IL-2 production in CMV-stimulated cells. Whole blood was stimulated with CMV antigen (3 ␮g/ml) with the addition of anti-CD28 and anti-CD49d antibodies (BD Pharmingen) at 3 ␮g/ml and analyzed by three-color flow cytometry. Unstimulated cells were exposed to costimulatory antibodies alone. Cells were gated on CD4⫹ cells, and histograms were generated based on the stains shown.

1. Adachi, Y., N. Oyaizu, S. Than, T. W. McCloskey, and S. Pahwa. 1996. IL-2 rescues in vitro lymphocyte apoptosis in patients with HIV infection. J. Immunol. 157:4184–4193. 2. Clerici, M., N. I. Stocks, R. A. Zajac, R. N. Boswell, D. R. Lucey, C. S. Via, and G. M. Shearer. 1989. Detection of three distinct patterns of T helper cell dysfunction in asymptomatic, human immunodeficiency virus-seropositive patients. J. Clin. Investig. 84:1892–1899. 3. Gea-Banacloche, J. C., S. A. Migueles, L. Martino, W. L. Shupert, A. C. McNeil, M. S. Sabbaghian, L. Ehler, C. Prussin, R. Stevens, L. Lambert, J. Altman, C. W. Hallahan, J. C. L. Bernaldo de Quiros, and M. Conners. 2000. Maintenance of large numbers of virus-specific CD8⫹ T cells in HIVinfected progressors and long-term nonprogressors. J. Immunol. 165:1082– 1092. 4. Goulder, P. J. R., M. A. Altfeld, E. S. Rosenberg, T. Nguyen, Y. Tang, R. L. Eldridge, M. M. Addo, S. He, J. S. Muckerjee, M. N. Phillips, M. Bunce, S. A. Kalams, R. P. Sekely, B. D. Walker, and C. Brander. 2001. Substantial differences in specificity of HIV-specific cytotoxic T cells in acute and chronic HIV infection. J. Exp. Med. 193:181–193. 5. Groux, H., G. Torpier, D. Monte, Y. Mouton, A. Capron, and J. C. Ameisen. 1992. Activation-induced death by apoptosis in CD4⫹ T cells from HIV-1 infected asymptomatic individuals. J. Exp. Med. 175:331–340. 6. Gurley, R. J., K. Ikeuchi, R. A. Byrn, K. Anderson, and J. E. Groopman. 1989. CD4⫹ lymphocyte function with early human immunodeficiency virus infection. Proc. Natl. Acad. Sci. USA 86:1993–1997. 7. Lane, C. L., J. M. Depper, W. C. Greene, G. Whalen, T. A. Waldmann, and A. S. Fauci. 1985. Qualitative analysis of immune function in patients with acquired immune deficiency syndrome. N. Engl. J. Med. 313:79–84. 8. Meyaard, L., S. A. Otto, R. R. Jonker, M. Janneke Mijnster, R. P. M. Keet, and F. Miedema. 1992. Programmed death of T cells in HIV-1 infection. Science 257:217–219. 9. Miedema, F., A. J. Chantal Petit, F. G. Terpstra, J. K. M. Eeftinck Schattenkerk, F. de Wolf, B. J. M. Al, M. Roos, J. M. A. Lange, S. A. Danner, J. Goudsmit, and P. T. A. Schellekens. 1988. Immunological abnormalities in human immunodeficiency virus (HIV)-infected asymptomatic homosexual men: HIV affects the immune system before CD4⫹ T helper cell depletion occurs. J. Clin. Investig. 82:1908–1914. 10. Musey, L. K., J. N. Krieger, J. P. Hughes, T. W. Schacker, L. Corey, and M. J. McElrath. 1999. Early and persistent human immunodeficiency virus type 1 (HIV-1)-specific T helper dysfunction in blood and lymph nodes following acute HIV-1 infection. J. Infect. Dis. 180:278–284. 11. Pitcher, C. J., C. Quittner, D. M. Peterson, M. Conners, R. A. Koup, V. C. Maino, and L. J. Picker. 1998. HIV-1-specific CD4⫹ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nat. Med. 5:518–525. 12. Seder, R. A., K. H. Grabstein, J. A. Berzofsky, and J. F. McDyer. 1995. Cytokine interactions in human immunodeficiency virus-infected individuals: roles of interleukin (IL)-2, IL-12, and IL-15. J. Exp. Med. 182:1067–1078. 13. Sieg, S. F., C. V. Harding, and M. M. Lederman. HIV-1 infection impairs cell cycle progression of CD4⫹ T cells without affecting early activation responses. J. Clin. Investig., in press. 14. Valdez, H., K. Y. Smith, A. Landay, E. Connick, D. R. Kuritzkes, H. Kessler, L. Fox, J. Spritzler, J. Roe, M. B. Lederman, H. M. Lederman, T. G. Evans, M. Heath-Chiozzi, and M. M. Lederman. 2000. Response to immunization with recall and neoantigens after prolonged administration of an HIV-1 protease inhibitor-containing regimen. ACTG 375 team. AIDS Clinical Trials Group. AIDS 14:11–21.